

ShareSoc

UK Individual Shareholders Society

5 Liberty Square, Kings Hill,
West Malling, ME19 4AU
Phone: 0333-200-1595
Web: www.sharesoc.org

SHARESOC GROWTH COMPANY SEMINAR

STOCKOPEDIA FINANCIAL ANALYSIS REPORTS ON PRESENTING COMPANIES

(Don't forget ShareSoc subscribing members can get a discount off the Stockopedia service).

Important Note: These reports do not necessarily reflect the latest changes in the financial position of the companies, for example any recent fund raisings, but are primarily based on the last annual financial statements and future forecasts.

Copies of the Powerpoint presentations given by presenters at these seminars are normally added to our website, here: <https://www.sharesoc.org/seminar/> soon after the Seminar, and are available to logged in full members of ShareSoc.

Use the page below and overleaf to take notes on the presentations.

ShareSoc Investment Warning - Company Presentations

No warranty is given by ShareSoc as to the reliability, accuracy or completeness of the information provided in presentations to investors by companies or by ShareSoc representatives in seminars organised or sponsored by ShareSoc. The information given in those seminars is provided for information purposes only and does not constitute investment, legal, tax or other advice or any recommendation to buy, or sell or otherwise transact in the shares of the companies presenting. Prospective investors should take appropriate professional advice before making any investment decision, or undertake their own further research. You are reminded that investment in the stock market carries substantial risks and share prices can go down as well as up. Past performance is not necessarily an indication of future performance.

Abingdon Health

ABDX  105p  0.0 0.0%

Highly Speculative, Small Cap,

Market Cap
Enterprise Value
Revenue
Market Cap Rank£100.5m Quality 0
£105.3m Value 0
£5.24m Momentum 0
th / 1806 **StockRank™** 0

Zoom 1m 3m 6m YTD 1y 2y 3y 5y All



Momentum

Relative Strength (%)

1m +15.4% 3m 1yr 

Volume Change (%)

10d v 3m


Price vs... (%)

52w High -23.2% 50d MA +4.36% 200d MA +4.36% 

Growth & Value

vs. industry vs. market

12m Forecast Rolling

PE Ratio (f) 17.8 PEG Ratio (f) 0.27 EPS Growth (f) 190.2 % Dividend Yield (f) n/a % 

Valuation (ttm)

Price to Book Value 36.5 Price to Tang. Book 36.5 Price to Free Cashflow 230.9 Price to Sales 19.2 EV to EBITDA n/a 

Quality

vs. industry vs. market

Return on Capital -83.2 % Return on Equity -76.4 % Operating Margin -63.3 % 

Health Trend

Piotroski F-Score 

5



Bankruptcy Risk

Altman Z1-Score 

n/a



Earnings Manipulation Risk

Low 

Magic Formula Score

n/a



Other Ratios

Leverage (ttm)	total	-intang	+pension
Gross Gearing	%		
Net Gearing	%		
Cash / Assets	%	40.0	40.0
Liquidity (ttm)	Efficiency (ttm)		
Curr. Ratio	n/a	Asset Turnover	0.95
Quick Ratio	n/a	Rec's Turnover	14.7
Interest Cov.	-52.8 	Stock Turnover	1.36

Recent History

vs. industry vs. market

Latest interim period (ended 30th Jun '20) vs. prior year

Sales Growth n/a % EPS Growth n/a % 

3yr Compound Annual Growth Rate

Sales Growth 55.6 % EPS Growth n/a % DPS Growth n/a % 

Margin of Safety (beta)

Relative to Sector -17% Graham Formula -49% 

Screens Passed

ABDX doesn't qualify for any screens.


Find out why: [View Checklists](#)

Financial Summary


Balance Sheet · Income Statement · Cashflow

Year End 30th Jun		2015	2016	2017	2018	2019	2020	2021E	2022E	CAGR / Avg
Revenue	£m	0.000	0.000	1.39	2.27	2.28	5.24	29.9	46.0	+55.6%
Operating Profit	£m	0.000	0.000	-2.40	7.36	-1.40	-3.31			
Net Profit	£m	0.000	0.000	-3.18	3.47	-1.26	-3.37			
EPS Reported	p	0.000	0.000	-3.33	3.63	-1.32	-3.53			
EPS Normalised	p	0.000	0.000	-3.33	-4.54	-1.32	-1.13	4.09	7.07	
EPS Growth	%								+72.9	
PE Ratio	x						n/a	25.7	14.9	
PEG	x						n/a	0.35	0.42	
Profitability										
Operating Margin	%			-172.8	324.5	-61.3	-63.3			+6.8%
ROA	%			-74.0	44.7	-17.7				
ROCE	%			-32.1	117.4	-21.5	-83.2			-4.8%
ROE	%				121.8	-21.2	-76.4			+6.1%
Cashflow										
Op. Cashflow ps	p	0.000	0.000	-1.73	-2.67	-0.95	2.19			
Capex ps	p	0.000	0.000	0.70	0.37	0.10	1.73			+35.4%
Free Cashflow ps	p	0.000	0.000	-2.43	-3.05	-1.05	0.45			
Dividends										
Dividend ps	p									
Dividend Growth	%									
Dividend Yield	%									
Dividend Cover	x									
Balance Sheet										
Cash etc	£m	0.000	0.000	2.03	0.48	0.87	4.39			+29.2%
Working Capital	£m	n/a	n/a	2.44	1.05	1.39	0.20			-56.7%
Net Fixed Assets	£m	0.000	0.000	0.39	0.62	0.57	3.01			+96.9%
Net Debt	£m	0.000	0.000	5.54	0.11	-0.35	0.38			
Book Value	£m	0.000	0.000	-0.12	5.81	6.09	2.75			
Average Shares	m	0.000	0.000	95.7	95.7	95.7	95.7			
Book Value ps	p	0.000	0.000	-0.12	6.07	6.36	2.87			

Graphical History Current Fiscal Year 2021



Broker Forecasts				30th Jun 2021			30th Jun 2022		
Price Target: N/A				Net Profit	EPS	DPS	Net Profit	EPS	DPS
Est. Long Term Growth Rate: n/a				(£)	(p)	(p)	(£)	(p)	(p)
Consensus Estimate				-	4.09	-	-	7.07	-
1m Change				-	-	-	-	-	-
3m Change				-	-	-	-	-	-



Profile Summary



Abingdon Health Ltd is a technology enabled lateral flow diagnostics company focused on developing, manufacturing and commercializing immunoassay tests and reader systems and provides lateral flow assay and reader contract services, and routine manufacturing services. It offers lateral flow reader assay original equipment manufacturer (OEM) solutions. Its lateral flow assay and reader services include later flow assay development, lateral flow manufacturing, quantitative lateral flow test reader customization, pharmaceutical diagnostic solutions and quotation request. Its products are AbC-19 Rapid Test, Nucleic Acid Lateral Flow Immunoassays and Seralite Free Light Chain (FLC) Serum. Abc-19 is a rapid test for the detection of IgG neutralizing antibodies to SARS-CoV-2 (COVID-19). Its Seralite Free Light Chain (FLC) product range is used as an aid in the diagnosis and management of multiple myeloma. The Seralite-FLC product range includes Seralite- FLC Serum and Seralite-FLC Urine.

Directors: Christopher Hand (CHM), Richard Marlow (FID), Christopher Yates (CEO) 41, Michael Hunter (OTH), Fiona Smith (DSL), Melanie Ross (CFO), Scott Page (SEC),

No. of Employees: 119

No. of Shareholders: n/a

Last Annual	June 30th, 2020	Sector	Healthcare
Last Interim	January 1st, 1970	Industry	Healthcare Equipment & Supplies
Incorporated	January 16, 2008	Index	
Shares in Issue	95,699,114	Exchange	London Stock Exchange (AIM)
Free Float	28.2m (29.5%)	Eligible for	an ISA? a SIPP?



Address York Biotech Campus Sand Hutton, YORK, YO41 1LZ, United Kingdom
Web <https://www.abingdonhealth.com/>
Phone +44 121 4145156
Contact ()
Auditors BDO LLP


ABDX Share Price Quote

ABDX Share Price
 GBP
105p
 Traded 4:06pm · Minimum 15 min delayed · NMS: 3.00k

Day's Change
 0.0 0.0%

Volume	Bid - Ask	Low - High	Spread
150,788	100.0 - 110.0	110.5 - 110.5	952bps
Avg Vol (3m)	Open - Close	12m Range	Beta
	105.0 - 105.0	92.0 - 136.6	0.00

ABDX Share Price Performance



Latest ABDX News Announcements (delayed)

[More »](#)

- Wed 12:00pm [Outsourcing vs Inhouse Resourcing For Lateral Flow Test Manufacturing](#)
- 27th Jan [Abingdon Health PLC - Media Clarification](#)
- 26th Jan [BRIEF-Abingdon Health Appoints New CFO](#)
- 26th Jan [Abingdon Health PLC - Trading Update](#)
- 26th Jan [Abingdon Health PLC - Appointment of Chief Financial Officer](#)

Upcoming ABDX Events

Recent ↓

Industry Peer Group	
	Rex Bionics Compare vs ABDX
	Bioquell Compare vs ABDX
	Truspine Technolog... Compare vs ABDX
	Proteome Sciences Compare vs ABDX
	Surgical Innovatio... Compare vs ABDX
	Immunodiagnostic S... Compare vs ABDX
	Inspiration Health... Compare vs ABDX
	Omega Diagnostics Compare vs ABDX
Healthcare Healthcare Equipment & Supplies	